Diamedica Therapeutics Stock Performance
| DMAC Stock | USD 8.10 0.08 0.98% |
On a scale of 0 to 100, DiaMedica Therapeutics holds a performance score of 7. The firm shows a Beta (market volatility) of 2.2, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, DiaMedica Therapeutics will likely underperform. Please check DiaMedica Therapeutics' information ratio, treynor ratio, and the relationship between the downside deviation and total risk alpha , to make a quick decision on whether DiaMedica Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in DiaMedica Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, DiaMedica Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.74 | Five Day Return (7.57) | Year To Date Return 3.15 | Ten Year Return 275.23 | All Time Return (80.09) |
Last Split Factor 1:20 | Dividend Date 2018-11-15 | Last Split Date 2018-11-15 |
1 | DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | 11/12/2025 |
2 | Disposition of 12000 shares by Parsons James T. of DiaMedica Therapeutics at 2.2 subject to Rule 16b-3 | 11/21/2025 |
3 | Acquisition by Stahlberg Jan of 40253 shares of DiaMedica Therapeutics at 7.8931 subject to Rule 16b-3 | 11/24/2025 |
4 | Acquisition by Stahlberg Jan of 73099 shares of DiaMedica Therapeutics at 8.5749 subject to Rule 16b-3 | 11/25/2025 |
5 | We Think DiaMedica Therapeutics Can Afford To Drive Business Growth | 12/01/2025 |
6 | Jan Stahlberg Acquires 40,253 Shares of DiaMedica Therapeutics Stock | 12/10/2025 |
7 | DiaMedica Therapeutics, Inc. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat | 12/19/2025 |
8 | Acquisition by Semba Charles Pauling of 3355 shares of DiaMedica Therapeutics at 8.42 subject to Rule 16b-3 | 01/02/2026 |
9 | DiaMedica Therapeutics Seen as Strong Performer with Upco - GuruFocus | 01/05/2026 |
10 | Acquisition by Giuffre Randall Michael of 32162 shares of DiaMedica Therapeutics at 4.11 subject to Rule 16b-3 | 01/06/2026 |
11 | DiaMedica Therapeutics Stock Price Down 2.3 percent - Should You Sell - MarketBeat | 01/09/2026 |
12 | Acquisition by Parsons James T. of 4287 shares of DiaMedica Therapeutics at 5.51 subject to Rule 16b-3 | 01/12/2026 |
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | 8.6 M |
DiaMedica | Build AI portfolio with DiaMedica Stock |
DiaMedica Therapeutics Relative Risk vs. Return Landscape
If you would invest 665.00 in DiaMedica Therapeutics on November 5, 2025 and sell it today you would earn a total of 153.00 from holding DiaMedica Therapeutics or generate 23.01% return on investment over 90 days. DiaMedica Therapeutics is currently generating 0.4603% in daily expected returns and assumes 4.8097% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than DiaMedica, and 91% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
DiaMedica Therapeutics Target Price Odds to finish over Current Price
The tendency of DiaMedica Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 8.10 | 90 days | 8.10 | about 42.16 |
Based on a normal probability distribution, the odds of DiaMedica Therapeutics to move above the current price in 90 days from now is about 42.16 (This DiaMedica Therapeutics probability density function shows the probability of DiaMedica Stock to fall within a particular range of prices over 90 days) .
DiaMedica Therapeutics Price Density |
| Price |
Predictive Modules for DiaMedica Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as DiaMedica Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.DiaMedica Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. DiaMedica Therapeutics is not an exception. The market had few large corrections towards the DiaMedica Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold DiaMedica Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of DiaMedica Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.28 | |
β | Beta against Dow Jones | 2.20 | |
σ | Overall volatility | 0.96 | |
Ir | Information ratio | 0.07 |
DiaMedica Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of DiaMedica Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for DiaMedica Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Parsons James T. of 4287 shares of DiaMedica Therapeutics at 5.51 subject to Rule 16b-3 |
DiaMedica Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of DiaMedica Stock often depends not only on the future outlook of the current and potential DiaMedica Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. DiaMedica Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 40.4 M | |
| Cash And Short Term Investments | 44.1 M |
DiaMedica Therapeutics Fundamentals Growth
DiaMedica Stock prices reflect investors' perceptions of the future prospects and financial health of DiaMedica Therapeutics, and DiaMedica Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on DiaMedica Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | 386.04 M | ||||
| Shares Outstanding | 52.08 M | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 8.11 X | ||||
| EBITDA | (26.64 M) | ||||
| Net Income | (24.44 M) | ||||
| Cash And Equivalents | 38.44 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 340 K | ||||
| Current Ratio | 25.50 X | ||||
| Book Value Per Share | 0.99 X | ||||
| Cash Flow From Operations | (22.08 M) | ||||
| Earnings Per Share | (0.71) X | ||||
| Market Capitalization | 418.7 M | ||||
| Total Asset | 46.34 M | ||||
| Retained Earnings | (140 M) | ||||
| Working Capital | 39.22 M | ||||
| Current Asset | 5.24 M | ||||
| Current Liabilities | 1.05 M | ||||
About DiaMedica Therapeutics Performance
By analyzing DiaMedica Therapeutics' fundamental ratios, stakeholders can gain valuable insights into DiaMedica Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if DiaMedica Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if DiaMedica Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.09 | 0.08 | |
| Return On Tangible Assets | (0.47) | (0.50) | |
| Return On Capital Employed | (0.75) | (0.79) | |
| Return On Assets | (0.47) | (0.50) | |
| Return On Equity | (0.54) | (0.57) |
Things to note about DiaMedica Therapeutics performance evaluation
Checking the ongoing alerts about DiaMedica Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for DiaMedica Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| DiaMedica Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (24.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| DiaMedica Therapeutics currently holds about 38.44 M in cash with (22.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.45. | |
| DiaMedica Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Parsons James T. of 4287 shares of DiaMedica Therapeutics at 5.51 subject to Rule 16b-3 |
- Analyzing DiaMedica Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether DiaMedica Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining DiaMedica Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating DiaMedica Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of DiaMedica Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of DiaMedica Therapeutics' stock. These opinions can provide insight into DiaMedica Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for DiaMedica Stock analysis
When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |